This inventor holds 1 USPTO granted patent. Top assignees: Cancer Research Campaign Tech (London), The University of Salford, University Technology Corporation. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2000
Title: The Innovations of Robert H Hargreaves
Introduction
Robert H Hargreaves is a notable inventor based in Bury, GB. He has made significant contributions to the field of anti-tumor agents, particularly through his innovative patent related to DT-diaphorase. His work has implications for cancer treatment, showcasing the importance of research in medical advancements.
Latest Patents
Hargreaves holds a patent for a novel benzoquinone, specifically 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone and its esters. This invention is designed to treat tumors that exhibit elevated levels of the enzyme DT-diaphorase. The potential applications of this compound could lead to improved therapeutic options for cancer patients.
Career Highlights
Throughout his career, Hargreaves has worked with prominent organizations such as Cancer Research Campaign Technology in London and University Technology Corporation. His experience in these institutions has allowed him to contribute to significant advancements in cancer research and treatment.
Collaborations
Hargreaves has collaborated with notable individuals in his field, including John Butler and David B Ross. These partnerships have likely enhanced the impact of his research and innovations.
Conclusion
Robert H Hargreaves is a distinguished inventor whose work in anti-tumor agents exemplifies the critical role of innovation in medicine. His contributions continue to influence cancer treatment strategies and highlight the importance of ongoing research in this vital area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile